ProCE Banner Activity

Phase III SEQUOIA Trial of Zanubrutinib vs Bendamustine and Rituximab in Previously Untreated CLL/SLL

Slideset Download
Conference Coverage
In patients with previously untreated CLL/SLL, zanubrutinib resulted in superior progression-free survival vs bendamustine plus rituximab.

Released: December 20, 2021

Expiration: December 19, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation